Nanjing Hongqiao Institute of Pharmaceutical Technology

Nanjing Hongqiao Institute of Pharmaceutical Technology is a specialized pharmaceutical research and development company based in Nanjing, China. Established in 2001, the institute focuses on the synthesis, formulation, and clinical application of small molecule drugs, particularly in the fields of oncology, cardiovascular health, and infectious diseases. It operates as both an independent developer of innovative and generic drugs and a Contract Research Organization (CRO) providing technical services to the broader pharmaceutical industry. The company is recognized for its expertise in high-end generic drug development and has successfully brought several products, such as Nafamostat mesylate, to the Chinese market. With a strong emphasis on chemical process optimization and regulatory compliance, the institute serves as a key player in the regional biotech ecosystem.